有：
PROVENGE® (sipuleucel-T) is the first autologous cellular immunotherapy
to receive FDA approval for the treatment of asymptomatic or minimally
symptomatic metastatic castrate resistant prostate cancer. PROVENGE is
designed to induce an immune response against prostate cancer.
